Asset Details
Do you wish to reserve the book?
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Do you wish to request the book?
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting calcitonin gene-related peptide: a new era in migraine therapy
2019
Overview
Migraine is one of the most prevalent and disabling diseases worldwide, but until recently, few migraine-specific therapies had been developed. Extensive basic and clinical scientific investigation has provided strong evidence that the neuropeptide calcitonin gene-related peptide (CGRP) has a key role in migraine. This evidence led to the development of small molecule CGRP receptor antagonists and monoclonal antibodies targeting either CGRP or its receptor. Clinical trials investigating these therapies have consistently shown statistically significant efficacy for either the acute or preventive treatment of migraine. No serious safety or tolerability issues have been identified in the trials of the monoclonal antibody therapies. Although the appropriate place of these new migraine-specific therapies relative to other available acute and preventive treatments remains to be determined, a growing body of evidence shows that therapeutic approaches targeting CGRP have the potential to transform the clinical management of migraine.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Calcitonin gene-related peptide
/ Calcitonin Gene-Related Peptide - antagonists & inhibitors
/ Calcitonin Gene-Related Peptide - metabolism
/ Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology
/ Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use
/ Headache
/ Humans
/ Migraine
/ Migraine Disorders - drug therapy
/ Migraine Disorders - metabolism
/ Molecular Targeted Therapy - methods
/ Peptides
/ Receptors, Calcitonin Gene-Related Peptide - metabolism
/ Small Molecule Libraries - pharmacology
